INmune Bio, Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

INmune Bio, a clinical-stage biotechnology company, has announced an underwritten public offering of common stock, subject to market conditions. The offering includes a 15% over-allotment option for underwriters. Proceeds will be used for working capital, corporate purposes, and to advance the company’s product candidates. The offering will utilize an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or buy securities in any jurisdiction where it would be unlawful.

Positive

• Intended use of proceeds includes advancing product development and expanding the pipeline.
• Company has an effective shelf registration statement, facilitating future financing.

Negative

• The public offering may lead to shareholder dilution.
• No assurance on the completion or terms of the offering, introducing uncertainty for investors.

LA JOLLA, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters an over-allotment option, exercisable for 45 days from the date of closing of the offering, to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions.

BTIG is acting as the sole book-running manager for the offering.

INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline.

The securities described above will be offered by the Company pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-237368) previously filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2020 and declared effective by the SEC on April 2, 2020.  The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC’s website at www.sec.gov or by contacting BTIG, LLC, Attention: Equity Capital Markets, 65 East 55th Street, New York, NY 10022, by telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com. 

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. 

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. 

INmune Bio Contact: 
David Moss, CFO (858) 964-3720
DMoss@INmuneBio.com

Investor Contact: 
James Carbonara (646) 755-7412
James@haydenir.com 

FAQ

What is the purpose of INmune Bio's public offering announced on July 15, 2020?

The public offering aims to raise funds for working capital, general corporate purposes, and to advance the development of its product candidates.

What is the size and structure of INmune Bio's offering?

The offering is underwritten and includes a 15% over-allotment option for underwriters.

How will INmune Bio's stock offering impact shareholders?

The stock offering may result in shareholder dilution, depending on the number of shares issued.

Is there any guarantee for the completion of INmune Bio's stock offering?

No, there is no assurance regarding the completion or terms of the offering; it is subject to market conditions.

Where can I find more details about INmune Bio's public offering?

Details will be available in a preliminary prospectus supplement and accompanying prospectus filed with the SEC.